A four-year analysis of an accelerated partial-breast irradiation (APBI) system has found that breast cancer recurrence rates following the delivery of APBI continue to be comparable to rates reported with standard radiation therapy.
Researchers analyzed data from patients enrolled in the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial. The data were collected from sites that were using the MammoSite APBI system (Hologic, Bedford, MA).
The study noted that in an analysis of the overall registry population, which includes a total of 1,440 patients with a median follow-up of 42 months, there was a three-year actuarial rate of ipsilateral breast tumor recurrence (IBTR) of 2.7%. The study also found a low incidence of axillary recurrence (0.6%).
Researchers concluded that treatment with the MammoSite system resulted in acceptable IBTR and axillary recurrence rates comparable to standard whole-breast radiation therapy, as well as excellent breast cancer-specific survival.
The results were presented by Dr. Peter Beitsch of Medical City Dallas Hospital at the recent American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting.
Related Reading
Hologic gets FDA nod for FRAX, September 9, 2008
Cytyc adds to Hologic Q3 revenues, July 31, 2008
Hologic completes tender offer for Third Wave, July 24, 2008
Hologic closer to Third Wave acquisition, July 17, 2008
Kubtec signs specimen x-ray deal with Hologic, July 14, 2008
Copyright © 2008 AuntMinnie.com
